NCT05392179Phase 2Completed

A Study in Subjects With Retinitis Pigmentosa

Study sponsor: Aldeyra Therapeutics, Inc. · ALDX

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2023-06-23Actual
Enrollment · participants8Actual
Source updated2026-04-23Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Number of participants with adverse events (AEs). After: Measure: Number of Subjects With Serious Adverse Events.

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview